TCM Biotech International

TCM Biotech International is a Taiwan-based biotech and healthcare company that combines drug development, diagnostics, manufacturing, and commercial distribution. The company is focused primarily on liver disease and liver cancer, with key internal programs including CatCHimera, a circulating ctDNA-based liver cancer detection platform, PTX-9908, a peptide drug for hepatocellular carcinoma, and U101, an oral non-antibiotic drug candidate for recurrent urinary tract infection. In parallel, TCM Biotech markets pharmaceuticals, medical devices, and functional health products through an established commercial channel in Taiwan. The company highlights a vertically integrated model spanning R&D, clinical development, manufacturing support, warehousing, and sales. It is publicly traded in Taiwan under ticker 4169.